NKTR and neoplasm: Bempegaldesleukin (NKTR-214 or BEMPEG), a novel CD122-preferential IL-2 pathway agonist, produces sustained signaling through the IL-2βγ receptor, which activates effector T and NK cells over regulatory T cells [59] and increases proliferation of TILs and PD-1 expression on effector T cells in the tumor microenvironment.